Atlanta, GA – 1st April, 2014— Personalized medicine and genomics company AKESOgen today announced that its CLIA-compliant laboratory has launched a new clinically validated cytogenomics microarray test. The test measures Copy Number Alterations (CNAs) across the genome utilizing Illumina’s CytoSNP 850K beadarray. The assay is validated across a wide spectrum of cancers e.g. solid tumors including breast, lung, brain and liquid tumors such as leukemias and lymphomas. It is also validated using a wide variety of starting materials including FFPE tissue, blood and bone marrow.
“We are delighted to launch our cytogenomic array test as it has enormous clinical utility – for prognosis and clinical work up. We believe we are the only commercial laboratory in the USA running this test on the Illumina platform utilizing FFPE tissue.” said Mark Bouzyk, CSO of AKESOgen.
About AKESOgen, Inc.
AKESOgen is an integrated genomics, genetics and biobanking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing and research. Based in Atlanta USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) to CLIA/GLP standards. For more information, visit www.akesogen.com.
Mark Bouzyk, PhD, Chief Scientific Officer. AKESOgen, Inc. +1 770-542-0890 ext 101 (office), or email@example.comShare this